Senate hears veterans’ push for state‑funded ibogaine clinical trials
Loading...
Summary
SB527 would create a grant program to support FDA‑regulated clinical research on ibogaine for treatment‑resistant conditions among veterans; veterans and advocacy groups testified about anecdotal benefits and early studies but stakeholders urged rigorous trials and guardrails.
Senate Bill 527 would authorize a veteran‑focused grant program to support FDA‑regulated clinical trials of ibogaine for opioid use disorder, PTSD and related conditions. Sponsor Sen. Kevin Harris said the program would fund clinical research at accredited Maryland institutions, limit recipients to in‑state reputable research entities, and include reporting and match requirements.
Veterans and advocacy groups — including several veteran witnesses who described personal recoveries after informal ibogaine treatments abroad — urged the committee to fund more rigorous local research. Dylan Hager of LEAP and Chase Rowan, a former Army Ranger who described a life‑changing ibogaine experience in Mexico, encouraged a structured, accountable clinical pathway rather than leaving veterans to seek treatments overseas.
Academic and policy witnesses (including a representative from the Reason Foundation) pointed to preliminary studies and biological mechanisms that warrant deeper investigation; supporters stressed guardrails such as grants only for reputable institutions, required matching funds, quarterly reporting and annual legislative review.
The committee sought questions but did not vote; witnesses acknowledged the need for strict regulatory guardrails, FDA oversight and careful program design to protect participants and ensure scientific validity.
